

# SANDOZ PHARMACEUTICALS

DIVISION OF INC.  
HANOVER, NEW JERSEY

August 13, 1957

117

3

Harold E. Smith, M.D.  
National Institute of Mental Health  
Addiction Center  
U. S. Public Health Service Hospital  
P.O. Box 2000  
Lexington, Kentucky

*See representative*

Dear Doctor Smith:

Late, but I hope not too late, I would like to thank you most sincerely for your splendid hospitality and the most interesting and stimulating discussion of our mutual problems.

I have just received a list from Basel which shows some new compounds which are available to you. Would you be kind enough to let us know which ones you would like to screen. I am sure that Basel will send us also acute toxicity data, which would enable you to get some ideas about their doses in humans. The different code numbers: MHA 61, MHA 74, MHA 10, MHA 75 stand for the following chemical names:

- MHA 61 - 1-methyl-2-bromo-lysergic acid diethylamide
- MHA 74 - 1-methyl-lysergic acid monoethylamide
- MHA 10 - 1-methyl-lysergic acid monoethylamide
- MHA 75 - 1-methyl-lysergic acid pyrrolidide.

Enclosed I am sending you also pharmacological data on three monoalkylamine derivatives, i.e., MHA 75, MHA 74 and MHA 10. We could furnish you with tablets containing 25 and 50 mg. of active ingredients as well as packages of 10 and 20 tablets.

Furthermore, I am sending you herewith an expert regarding MHA 75. He talked about this compound briefly in Chicago as well as in Lexington. We would appreciate it very much if you would include this compound in your screening program. What do you think about whether in addition to studying effects it also possesses parasympathetic properties. I could send you 5 mg. tablets as well as pure substance.

For all the data mentioned above, I am sure you will be very interested. If you wish, we can also send you the materials you would like to have. I am sure you will be very interested.

3-4107

I have just read with great interest an article which deals with abuse of analgesics in Switzerland and which appeared in the Schweizerische Aerztezeitung 74:207 (July 5) 1957 "Erschubung uober Ananase, Verbreitung und Prophylaxe des Medikamenten-, Insbesondere des analgetikamissbrauchs in der Schweiz". I thought that you, too, would be interested in this subject and, therefore, I am sending you herewith a verifax copy of the article.\*

Just in case you have in mind to go to Switzerland, I am sending you a small booklet in English which briefly describes Switzerland from diff. and aspects.

I enclose also our "Swissair Agent's Special" which I thought might be of interest to you and which you might like to have for your files.

I would be in a position to prepare an exposé dealing with the antisergeric blocking effects of error alkaloids in animals and humans. Would you please let me know whether you would like to have it?

I hope that I did not forget to mention you in my very cordial and sincere regards, and that I have not overlooked anything of importance to you.

I wrote to you last regarding the various analogues of the lysergic acid nucleus. I am now writing you again regarding the various analogues available, especially analogues with changes in position 1 and/or 2 in the lysergic acid nucleus.


The only wish I have is to have the opportunity to see you soon again, and in the meantime, I am, with my very best regards,

Yours grateful,

R. Birchler, M.D.  
Medical Director.


\* under separate cover.

4-406



MBL 61


530



WHLA 74

830

IAE- deriv.  
(IAE antisera  
index= 11-12



ALA 10


40



Index 25.


A-405

Copied: Page 2/2/17




Fa. Lab.  
No. 8154

Pharmacological tests  
not yet available



No. 8154



No. 8157

Copies: State - 20.000 10/7